The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
Open accessAbstract
To determine if the clearance of hepatitis C genotype 1 virus (HCV) is dependent on the dose of interferon alfa-2b (IFN-α2b), the acute clearance of HCV after a single dose of either 3, 5, or 10 mIU of IFN-α was compared in patients with chronic hepatitis C. HCV-RNA levels following IFN-α administration were measured. At 24 hours, mean percentage serum viral reduction was 41.4%, 63.7%, and 85.5% for 3, 5, and 10 mIU, respectively (P < .001). At 48 hours, the mean viral reduction was consistently less than the reduction at 24 hours, averaging 22.9%, 61.9%, and 74.3%, respectively (P < .001), indicating that the drug effect diminishes before 48 hours. Regression analysis showed a positive correlation between dose and percent reduction of HCV- RNA levels (r = .6; P < .001). A mathematical model showed that such dose dependence is expected if IFN-α partially blocks viral production. Minimum clearance and production rates of HCV were estimated from measurements of HCV-RNA levels after the 10-mIU dose. HCV decay followed an exponential decline with a minimum estimate of the viral clearance rate constant of 2.8 per day, corresponding to a virion half-life of 0.3 days or less. A minimal estimate of the daily HCV production and clearance is 3.7 × 10 11 virions per day, indicating a high rate of replication and turnover. These results indicate that there is a dose-dependent effect of IFN-α in clearance of HCV genotype 1. Because the virion production rate is very rapid and because the current recommended dose of IFN-α (3 mIU) is often ineffective, larger doses should be considered to treat genotype 1-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Self-citationHIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Self-citationKnodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Okamoto, H., Sugiyama, Y., Okada, S., Kurai, K., Akahane, Y., Sugai, Y., Tanaka, T., Sato, K., Tsuda, F., Miyakawa, Y., et al. (1992) · Journal of General Virology · doi:10.1099/0022-1317-73-3-673 · Cited by 1,242
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
Lau, J. Y. N., Davis, G. L., Kniffen, J., Qian, K.-P., Urdea, M. S., Chan, C. S., Neuwald, P. D., Wilber, J. C., & Mizokami, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90635-t · Cited by 795
Yoshioka, K., Kakumu, S., Wakita, T., Ishikawa, T., Itoh, Y., Takayanagi, M., Higashi, Y., Shibata, M., & Morishima, T. (1992) · Hepatology · doi:10.1002/hep.1840160203 · Cited by 668
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.
Ogata, N., Alter, H. J., Miller, R. H., & Purcell, R. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3392 · Cited by 606
Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
Hagiwara, H., Hayashi, N., Mita, E., Takehara, T., Kasahara, A., Fusamoto, H., & Kamada, T. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91025-d · Cited by 377
Okada, S., Akahane, Y., Suzuki, H., Okamoto, H., & Mishiro, S. (1992) · Hepatology · doi:10.1002/hep.1840160302 · Cited by 286
Gretch, D. R., Bacchi, C. E., Corey, L., Rosa, C. D., Lesniewski, R. R., Kowdley, K., Gown, A., Frank, I., Perkins, J. D., & Carithers, R. L. (1995) · Hepatology · doi:10.1002/hep.1840220102 · Cited by 188
Self-citationEnomoto, N., Kurosaki, M., Tanaka, Y., Marumo, F., & Sato, C. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-6-1361 · Cited by 183
Sáez-Royuela, F., Porres, J. C., Moreno, A., Castillo, I., Martinez, G., Galiana, F., & Carreño, V. (1991) · Hepatology · doi:10.1016/0270-9139(91)92448-h · Cited by 116
Gretch, D. R., Lee, W., & Corey, L. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.8.2145-2149.1992 · Cited by 112
Self-citationEnomoto, N., Sato, C., Kurosaki, M., & Marumo, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80066-2 · Cited by 38
Cited by
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Self-citationPeginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., & Manns, M. P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011232 · Cited by 800
Metadata
- Authors
- Lam, N. P., Neumann, A. U., Gretch, D. R., Wiley, T. E., Perelson, A. S., & Layden, T. J.
- Venue
- Hepatology
- Published
- 1997-07
- Volume
- 26
- Issue
- 1
- Pages
- 226-231
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2079771726
- Cited by
- 329
- References
- 17
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.